OBJECTIVE: Low plasma levels of IGF-I, particularly when coupled with low levels of the potentially inhibitory IGF binding protein (IGFBP)-1 and higher levels of C-reactive protein (CRP), have been implicated in the pathogenesis of metabolic syndrome X and cardiovascular disease. We report the relative contributions of IGFBP-1 and CRP to the occurrence of the metabolic syndrome in a healthy population cohort to establish the extent to which these factors may contribute to subsequent risk of cardiovascular disease. RESEARCH DESIGN AND METHODS: The volunteers in the study were all participants in the Ely study, a continuing population-based cohort in Ely, Cambridgeshire, U.K. Of 839 individuals studied, 154 (18.4%) fulfilled criteria for the metabolic syndrome. RESULTS: Subjects with the metabolic syndrome had lower IGFBP-1 (14.4 microg/l [95% CI 12.9-16.0] vs. 25.4 [24.1-26.7], P < 0.001) and higher CRP (1.9 mg/l [1.6-2.2] vs. 1.0 [0.9-1.1], P < 0.001). Logistic regression, adjusted for age, sex, fasting insulin, and IGF-I, demonstrated a striking 14-fold increased risk for the metabolic syndrome (odds ratio 14.1 [4.1-48.4], P < 0.001) in individuals with a CRP value in the highest tertile and IGFBP-1 levels below the median. CONCLUSIONS: The combination of a high CRP concentration coupled with a low IGFBP-1 results in a dramatic increase in an individual's risk of having the metabolic syndrome. Further elucidation of the biological processes linking the IGF and inflammatory systems may allow the identification of novel therapeutic targets for cardiovascular risk reduction.
OBJECTIVE: Low plasma levels of IGF-I, particularly when coupled with low levels of the potentially inhibitory IGF binding protein (IGFBP)-1 and higher levels of C-reactive protein (CRP), have been implicated in the pathogenesis of metabolic syndrome X and cardiovascular disease. We report the relative contributions of IGFBP-1 and CRP to the occurrence of the metabolic syndrome in a healthy population cohort to establish the extent to which these factors may contribute to subsequent risk of cardiovascular disease. RESEARCH DESIGN AND METHODS: The volunteers in the study were all participants in the Ely study, a continuing population-based cohort in Ely, Cambridgeshire, U.K. Of 839 individuals studied, 154 (18.4%) fulfilled criteria for the metabolic syndrome. RESULTS: Subjects with the metabolic syndrome had lower IGFBP-1 (14.4 microg/l [95% CI 12.9-16.0] vs. 25.4 [24.1-26.7], P < 0.001) and higher CRP (1.9 mg/l [1.6-2.2] vs. 1.0 [0.9-1.1], P < 0.001). Logistic regression, adjusted for age, sex, fasting insulin, and IGF-I, demonstrated a striking 14-fold increased risk for the metabolic syndrome (odds ratio 14.1 [4.1-48.4], P < 0.001) in individuals with a CRP value in the highest tertile and IGFBP-1 levels below the median. CONCLUSIONS: The combination of a high CRP concentration coupled with a low IGFBP-1 results in a dramatic increase in an individual's risk of having the metabolic syndrome. Further elucidation of the biological processes linking the IGF and inflammatory systems may allow the identification of novel therapeutic targets for cardiovascular risk reduction.
Authors: Sally L Ricketts; Katrijn L Rensing; Jeff M Holly; Li Chen; Elizabeth H Young; Robert Luben; Sofie Ashford; Kijoung Song; Xin Yuan; Abbas Dehghan; Benjamin J Wright; Dawn M Waterworth; Vincent Mooser; Gérard Waeber; Peter Vollenweider; Stephen E Epstein; Mary S Burnett; Joseph M Devaney; Hakon H Hakonarson; Daniel J Rader; Muredach P Reilly; John Danesh; Simon G Thompson; Alison M Dunning; Cornelia M van Duijn; Nilesh J Samani; Ruth McPherson; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu Journal: Int J Mol Epidemiol Genet Date: 2011-08-03
Authors: Lorraine E Levitt Katz; Kevin A Gralewski; Pamela Abrams; Preneet C Brar; Paul R Gallagher; Terri H Lipman; Lee J Brooks; Dorit Koren Journal: Pediatr Diabetes Date: 2014-12-10 Impact factor: 4.866
Authors: Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler Journal: Diabetes Metab Res Rev Date: 2009-01 Impact factor: 4.876
Authors: A Caixàs; O Giménez-Palop; M Broch; C Vilardell; A Megía; I Simón; G Giménez-Pérez; D Mauricio; J Vendrell; C Richart; J M González-Clemente Journal: J Endocrinol Invest Date: 2008-02 Impact factor: 4.256
Authors: Swapnil N Rajpathak; Aileen P McGinn; Howard D Strickler; Thomas E Rohan; Michael Pollak; Anne R Cappola; Lewis Kuller; XiaoNan Xue; Anne B Newman; Elsa S Strotmeyer; Bruce M Psaty; Robert C Kaplan Journal: Growth Horm IGF Res Date: 2007-09-27 Impact factor: 2.372
Authors: Michael P Brugts; Cornelia M van Duijn; Leo J Hofland; Jacqueline C Witteman; Steven W J Lamberts; Joseph A M J L Janssen Journal: Diabetes Date: 2010-02 Impact factor: 9.461